BCL2 and lymphoma: Genome-scale loss- and gain-of-function genetic modifier screens in a BCL-2 driven lymphoma cell line as well as an integrated expression profile analysis identified overexpression of MCL-1 and sequestration of BIM as an adaptive mechanism of resistance to venetoclax70.